ViRexx Partner Presents at Annual Conference of The American Association of Cancer Research.EDMONTON, Alberta -- ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments of cancer and chronic hepatitis B and C and embolotherapy treatments of tumors today announced that its partner Unither Pharmaceuticals, Inc. presented an abstract at the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ) Annual Meeting held in Anaheim, California. Birgit Schultes, Ph.D., Senior Director of Research at Unither Pharmaceuticals presented the abstract on April 18th as part of the conference proceedings covering "Regulatory and Effector effector /ef·fec·tor/ (e-fek´ter) 1. an agent that mediates a specific effect. 2. an organ that produces an effect in response to nerve stimulation. T Cells in Tumor Immunity". ViRexx's partner Unither Pharmaceuticals, a subsidiary of United Therapeutics Corporation, is funding the development of a number of immunotherapy candidates including the Phase III candidate OvaRex(R) MAb. The abstract outlines preclinical results for the monoclonal antibody MAb AR20.5, BrevaRex(R) MAb. The study demonstrates that MUC-1 in the form of an immune complex is more efficiently processed than MUC-1 alone, leading to T helper cell T helper cell see helper lymphocyte. stimulation and an enhanced cytotoxic T lymphocyte cytotoxic T lymphocyte CTL, cytotoxic T cell Immunology A subset of T cells with a CD8 receptor on the surface that recognizes and lyses malignant or virally-infected self cells bearing self, ie 'haplotype restricted', class I MHC molecules. (CTL See control key. 1. CTL - Checkout Test language. 2. CTL - Compiler Target Language. 3. CTL - Computational Tree Logic ) response. ViRexx has also completed a Phase I dose comparison study of MAb AR20.5, BrevaRex(R) MAb, in patients with MUC-1 expressing tumors. BrevaRex(R) MAb is an immunotherapy candidate to treat breast, pancreatic, lung, colon and other cancers expressing MUC-1. "Unither's presentation supports our belief that the therapeutic use of murine antibodies can enhance immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. of antigen or cell-based vaccines in vivo and can work in combination with chemotherapy treatments," commented Mr. Marc Canton, President and COO of ViRexx. "Unither's murine monoclonal antibody research, and our partnership with Unither on a number of immunotherapy candidates, is an important component of our broad product pipeline for the treatment of cancer and viral infections." About ViRexx Medical Corp. ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B & C & solid tumors. ViRexx's lead product, OvaRex(R) MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the funded by ViRexx's partner United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com. THE TSX HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION CONTAINED HEREIN ViRexx Medical Corp. (TSX:VIR) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion